Gene · 7321
UBE2D1: ubiquitin conjugating enzyme E2 D1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. UBE2D1: ubiquitin conjugating enzyme E2 D1. Genes, record 7321. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7321
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P51668 | Ubiquitin-conjugating enzyme E2 D1 | 147 | 14 | Ensembl, GeneID, HGNC |
Source UniProt
Patents38
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026063204 A | 2026-04-10 | 4 | P51668 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69057 | P51668 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 9397 | P51668 | Espacenet |
| WO 2025125630 A1 | 2025-06-19 | 100 | P51668 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 9397 | P51668 | Espacenet |
| EP 4437343 A1 | 2024-10-02 | 4 | P51668 | Espacenet |
| JP 2023550743 A | 2023-12-05 | 70 | P51668 | Espacenet |
| JP 2023097901 A | 2023-07-10 | 5 | P51668 | Espacenet |
| JP 2023504790 A | 2023-02-07 | 14 | P51668 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 95125 | P51668 | Espacenet |
1 to 10 of 38
See all 38 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,455
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | UBE2D1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA021765 | Cancer Center Support Grant (CCSG) | 13 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 10 | 2025 |
| R01HL096376 | E3 Ligase-Mediated Immunosuppression in Acute Lung Injury | 9 | 2025 |
| R01HL097376 | Sepsis-Associated Immune Suppression and F-box Proteins | 9 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| P30DK026743 | UCSF Liver Center | 8 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 6 | 2025 |
| R01CA240981 | Harnessing E3 Ligases for Cancer Therapy | 6 | 2025 |
| R35GM128855 | Spindle Assembly Checkpoint Silencing | 5 | 2025 |
1 to 10 of 1,455Source NIH's project files
See all 1,455 nih grantsPapers1,643
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Predictive molecular signatures for successful tapering of canakinumab in systemic juvenile idiopathic arthritis. | Ann Rheum Dis | 2026 | 42772990 | PubTator, text mining | PubMed |
| Fluorophore placement and size impact E2 ubiquitination efficiency. | Biochem J | 2026 | 42770861 | PubTator, text mining | PubMed |
| Discovery of hub genes linking oxidative stress to type 2 diabetic sarcopenia using single-cell sequencing and machine learning. | PLoS One | 2026 | 42412755 | PubTator, text mining | PubMed |
| Protocol for integrated ubiquitination analysis of in vitro E3 ligase-DUB regulation and in vivo ubiquitin chain linkage characterization. | STAR Protoc | 2026 | 42397747 | PubTator, text mining | PubMed |
| Erratum: IGF2BP2-modified UBE2D1 Interacts with Smad2/3 to Promote the Progression of Breast Cancer. | Am J Cancer Res | 2026 | 42266759 | PubTator, text mining | PubMed |
| CD14+CXCL10+ monocytes are associated with peripheral immune network alterations in systemic juvenile idiopathic arthritis: From multiple centers. | Genes Dis | 2026 | 42004226 | PubTator, text mining | PubMed |
| Liquid-liquid phase separation couples MKRN2-mediated ubiquitination of CSDE1 with neurodevelopmental disorders. | Front Cell Neurosci | 2026 | 41757349 | PubTator, text mining | PubMed |
| High UBE2D1 expression is associated with poor prognosis and immunotherapy resistance in head and neck cancer. | J Oral Biol Craniofac Res | 2026 | 41732664 | PubTator, text mining | PubMed |
| Structure-guided analysis and prediction of human E2-E3 ligase pairing specificity. | bioRxiv | 2026 | 41726935 | PubTator, text mining | PubMed |
| Emerging biologic modalities for targeted protein degradation. | J Biol Chem | 2026 | 41651431 | PubTator, text mining | PubMed |
1 to 10 of 1,643
See all 1,643 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7321
GET https://conductscience.org/api/genes/v1/7321/patents?page=2